The rising interest in GLP-1 agonists for diabetes has generated a question about application forms : patches versus tablets . Traditionally , GLP-1 treatments were only available in oral form, but the introduction of skin applications offers a different choice . Patches might benefit individuals facing challenges swallowing tablets , those wanting